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ABSTRACT
Primary biliary cholangitis (PBC), previously known as primary biliary cirrhosis, is an autoimmune liver 
disease which tends to be chronic and progressive in nature that is marked by the presence of cholangitis and 
small size biliary duct destruction which may cause cirrhosis or even liver failure. PBC incidence increases 
because PBC can now be diagnosed earlier and is due to the increasing survival rate of PBC patients. Diagnosis 
of PBC can be confirmed in asymptomatic state if in the indirect immunofluorescence (IIF) examination revealed 
antimitochondrial antibody (AMA) positive, and there is an abnormal liver function. Etiopathogenesis of PBC 
is multifactorial which involves genetic and environmental factors. Genetic factors which contribute to the 
incidence of PBC are human leukocyte antigen (HLA) and non-HLA genes, while in the environmental factors, 
the triggering factors of PBC are bacterial infection and xenobiotic. Interaction of these factors causes the 
development of E2 subunit pyruvate dehydrogenase complex (PDC-E2) and AMA as the causing autoantigen 
of biliary duct desctruction in PBC, mediated by the immune system. PBC stage is divided into minimal, mild, 
moderate and severe. Ursodeoxycholic acid (UDCA) is the first line therapy for PBC, while obeticholic acid 
(OCA) and fibrate is used as the second line. Liver transplantation is the definitive therapy for PBC where disease 
progresses into the advanced stage, although the patients have received medical treatment. 
Keywords: primary biliary cholangitis (PBC), pyruvate dehydrogenase complex (PDC-E2), antimitochondrial 
antibody (AMA), Ursodeoxycholic acid (UDCA)
ABSTRAK
Primary biliary cholangitis (PBC) yang sebelumnya dikenal dengan primary biliary cirrhosis merupakan penyakit 
hati autoimun yang bersifat kronis dan progresif, ditandai dengan adanya cholangitis dan destruksi duktus bilier 
ukuran kecil yang dapat menyebabkan sirosis sampai dengan gagal hati. Insidensi PBC mengalami peningkatan 
disebabkan karena PBC sudah dapat didiagnosis lebih dini dan peningkatan angka bertahan hidup penderita PBC. 
Diagnosis PBC dapat ditegakkan pada status asimtomatik jika dalam pemeriksaan indirect immunofluorosence (IIF) 
didapatkan antimitochondrial antibody (AMA) positif dan terdapat fungsi hati yang abnormal. Etiopatogenesis 
PBC multikompleks yaitu faktor genetik dan faktor lingkungan. Faktor genetik yang berkontribusi terhadap 
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kejadian PBC yaitu gen human leukocyte antigen (HLA) dan non HLA, sedangkan faktor lingkungan yang sebagai 
pemicu terjadinya PBC yaitu infeksi bakteri dan xenobiotik. Interaksi faktor ini menyebabkan terbentuknya pyruvat 
dehydrogenase complex subunit E2 (PDC-E2) dan AMA sebagai autoantigen penyebab kerusakan duktus bilier 
pada PBC yang diperantarai oleh sistem imun. Stadium PBC dibagi menjadi minimal, ringan, sedang dan berat. 
Ursodeoxycholic acid (UDCA) merupakan terapi lini pertama untuk PBC sedangkan obeticholic acid (OCA) dan 
fibrat digunakan sebagai terapi lini kedua. Transplantasi hati merupakan terapi definitif pada PBC yang berkembang 
ke stadium lanjut walaupun sudah mendapatkan terapi medikamentosa. 
Kata kunci: primary biliary cholangitis (PBC), pyruvate dehydrogenase complex (PDC-E2), antimitochondrial 
antibody (AMA), ursodeoxycholic acid (UDCA)
INTRODUCTION
Primary biliary cholangitis is a liver autoimmune 
disease which is chronic and progressive in 
characteristic, marked by the presence of cholangitis 
as well as small and medium biliary duct destruction 
which eventually causes cirrhosis or even liver 
failure.1-2 The characteristics of this disease is the 
reactivity of specific antimitochondrial antibody 
(AMA) (> 90%), increase of alkaline phosphatase 
(ALP) with histopathological appearance of biliary 
duct destruction and lymphocytic chronic non-
suppurative, granulomatous cholangitis.3
The incidence and prevalence of primary biliary 
cholangitis (PBC) increases as the capacity of earlier 
diagnosis and the survival rate of PBC patients increase, 
with yearly incidence and prevalence of 0.07-4.9 cases 
per 100,000 and 2.7-40 cases per 100,000, respectively. 
Primary biliary cholangitis is more common in 
females, with the ratio of female:male of 10:1 and in 
average occurs in the age of ± 50 years.4 Based on the 
data in Anatomical Pathology Department Faculty of 
Medicine Universitas Indonesia/Cipto Mangunkusumo 
Hospital, there were only 3 cases diagnosed as PBC in 
the year 2007-2017.
The exact pathogenesis of PBC is still unclear. 
Genetic and environmental interaction become the 
aetiological factors of inflammation and destruction 
that leads to ductopenia. Genetic factors in PBC, which 
is the presence of change in X chromosome also related 
to human leucocyte antigen (HLA) and non HLA, 
while the environmental factor is supported by the 
molecular mimicry theory due to bacterial infection 
and xenobiotic compounds.2,5 The pathological process 
in biliary duct is mediated by the adaptive immune 
response (humoral and cellular) and natural immune 
response which attack the biliary epithelial cells due to 
the loss of self-tolerance towards E2 subunit pyruvate 
dehydrogenase complex (PDC-E2) autoantigen.5 The 
characteristics of biliary epithelial cells, apoptotic 
theory, and senescence in biliary epithelium are the 
reasons why biliary epithelial cells become the specific 
target in immune response although PDC-E2 is located 
in the mitochondria.3 This literature review is aimed 
to discuss clinical, histopathological, and immune 
mechanism aspects in the pathogenesis of PBC. 
Definition of Primary Biliary Cholangitis (PBC)
Primary biliary cholangitis is an autoimmune liver 
disease which is chronic and progressive, marked by 
the presence of cholangitis and small to medium biliary 
duct destruction (< 100 µm) and may progress into 
ductopenia, fibrosis, cirrhosis, and liver failure.4 This 
disease is previously known as primary biliary cirrhosis. 
The changes in its nomenclature occur after a several of 
PBC patient were found to be not having cirrhosis. The 
presence of better screening and diagnostic tool enables 
the PBC diagnosis to be confirmed in early stage, while 
cirrhosis occur in advanced stage. 4,6
Clinical Symptoms and Signs of Primary Biliary 
Cholangitis (PBC)
Primary biliary cholangitis comprises of four phases, 
which are preclinical/silent, asymptomatic, symptomatic, 
and pre-terminal or liver failure phase (figure 1). It is 
unnecessary for patient to follow all through available 
phases. Silent phase is characterized by positive AMA, 
but the liver function results are still normal. Patient 
who is diagnosed in the silent phase may survive up to 
22 years without treatment, while in asymptomatic and 
symptomatic phase patient may survive in the range of 
6-10 years. Asymptomatic phase is temporary and may 
develop into symptomatic phase after 4-18 years. Five 
percent of asymptomatic phase patients persist in this 
phase for 20 years. Cirrhosis is estimated to happen after 
10 years in patients with asymptomatic PBC.4
PBC patient is frequently diagnosed in asymptomatic 
state (50-60%), which is a condition in which liver 
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function is abnormal but no clinical symptoms 
was observed. In Western countries and Japan, 
approximately 85% of PBC patients can be diagnosed 
in asymptomatic phase, while in other Asian countries 
only 20-74% patients can be identified in this 
phase.9 Fatigue and pruritus are the most common 
symptoms in PBC. Other clinical symptoms are skin 
hyperpigmentation, xanthelasma, hyperlipidemia, 
osteoporosis, and fat-soluble vitamin deficiency.1,4 
In terminal stage, splenomegaly and liver cirrhosis 
are found. Splenomegaly usually signifies the 
presence of portal hypertension. Portal hypertension 
gives poor prognosis in PBC. Signs of liver cirrhosis 
include ascites, jaundice, hepatic encephalopathy, 
and upper gastrointestinal tract bleeding. PBC patient 
with cirrhosis is at risk to suffer from hepatocellular 
carcinoma.4
Based on the activity of necroinflammation and 
histopathology variation, Nakanuma et al divide the 
PBC stages into minimal, mild, moderate, and severe. 
Necroinflammation activity refers to the area of 
cholangitis and hepatitis (interface hepatitis and lobular 
inflammation). Variation of histopathology comprises 
of three components, which are fibrosis, ductopenia, 
and copper precipitate (sign of chronic cholestasis) 
appearance.7 Classification of PBC stage according 
to Scheuer and Nakanuma is summarized in table 1.8
Table 1. Histopathological staging system of primary biliary 
cholangitis (PBC) 8
Stage Scheuer Nakanuma
Stage I Florid duct lesions, 
biliary duct destruction, 
inflammation of the 
portal
No or minimal progression
(fibrosis, ductopenia, copper 
binding protein = 0)
Stage 2 Duct proliferation, 
widening of the portal, 
interface hepatitis
Mild progression 
(fibrosis, ductopenia, copper 
binding protein = 1-3)
Stage 3 Scarring, ductopenia Moderate progression
(fibrosis, ductopenia, copper 
binding protein = 4-6)
Stage 4 Cirrhosis Advanced progression
(fibrosis, ductopenia, copper 
binding protein = 7-9)
Figure 1. Clinical phase of primary biliary cholangitis (PBC)4
Diagnosis of Primary Biliary Cholangitis (PBC)
Diagnosis of PBC is confirmed by AMA examination 
using indirect immunofluorescence method with AMA 
titre ≥ 1:40 or AMA level > 0.1 unit, and the increase 
of alkaline phosphatase (ALP) > 1.5x normal for 
six consecutive months, and the increase of gamma 
glutamyltransferase (GGT).4
In PBC, the increase of aspartate aminotransferase 
(AST) and alanine aminotransferase (ALT) may also 
happen, but less than 3x normal limit (< 300IU/L). 
ALP and bilirubin values are still in normal limit 
in early stage of PBC. The significant increase of 
ALP characterizes the severity of ductopenia and 
inflammation, while the gradual increase of bilirubin 
(< 20 mg/dL) follows the progressivity of the disease.1,4
Liver biopsy is required in several conditions, like 
in patient who has clinical symptoms of PBC with 
negative AMA. It also needed in patient with positive 
AMA, but the increase of ALP is < 1.5x normal limit 
and/or AST and ALT increases ≥ 5x normal limit with 
the significant increase of Immunoglobulin G (IgG). In 
addition to diagnosis purposes, liver biopsy is used to 
provide stage information as an evaluation of disease 





Figure 2. PBC stage according to Scheuer. A. Florid duct lesions. B and C. Biliary duct destruction 
and portal inflammation. D. Ductular proliferation (HE, 100x). E. Portal fibrosis and ductopenia 
(Masson trichome, 40x). F. Cirrhosis.4,8 
 
Variation of Primary Biliary Cholangitis (PBC) 
PBC with negative AMA  
The prevalence of this variation of PBC is 5%-10% of total patients with PBC. The 
characteristics of this variant is that it has clinical and histopathology appearance of PBC 
but negative AMA, and tends to have positive ANA. This variant PBC slightly differ from 
positive AMA PBC in terms of clinical progression and response to therapy.4,9
Positive AMA PBC with no clinical symptom  
The prevalence of this variation of PBC is 0.5%. It has several with characteristics like 




Based on the development of lesion in the portal 
tract, Scheuer classified PBC into 4 stages (figure 
2). In stage 1, there are florid duct lesions, biliary 
duct destruction, inflammation of the portal. Stage 
2 is characterized by duct proliferation. Stage 3 is 
characterized by the presence of portal fibrosis and 
ductopenia and in stage 4, cirrhosis has occurred.8 
Figure 2. PBC stag  according to Sch uer. A. Florid duct lesions. 
B and C. Biliary duct d s ruction and portal inflamm tion. 
D. Ductular proliferation (HE, 100x). E. Portal fibrosis and 
ductopenia (Masson trichome, 40x). F. Cirrhosis.4,8
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Variation of Primary Biliary Cholangitis (PBC)
Primary biliary cholangitis (PBC) with negative 
antimitochondrial antibody (AMA) 
The prevalence of this variation of PBC is 5-10% 
of total patients with PBC. The characteristics of 
this variant is that it has clinical and histopathology 
appearance of PBC but negative AMA, and tends 
to have positive antinuclear antibodies (ANA). This 
variant PBC slightly differ from positive AMA PBC in 
terms of clinical progression and response to therapy.4,9 
Positive antimitochondrial antibody (AMA) primary 
biliary cholangitis (PBC) with no clinical symptom 
The prevalence of this variation of PBC is 0.5%. 
It has several with characteristics like the absence of 
PBC symptoms, normal ALP with liver function, and 
positive AMA. This variant PBC can develop into 
symptomatic phase in 4-18 years time (36-89%), thus 
it is recommended that patient with this variant to 
undergo annual follow-up.4 
Primary biliary cholangitis-autoimmune hepatitis 
(PBC-AIH) overlap syndrome
Overlap syndrome happens if there is PBC and AIH 
characteristics concurrently. The prevalence of this 
variant of PBC is 10%. This variant of PBC has higher 
risk towards fibrosis, portal hypertension, thus it has 
high possibility to be needing a liver transplantation. 
Therapy of this variant of PBC is the combination of 
UDCA and immunosuppressant with the aim to slow 
the progressivity of fibrosis. To diagnose this variant 
of PBC, clinical accuracy from hepatologist and 
information accuracy from pathologist are needed.6 
Autoantibody and Autoantigen in Primary Biliary 
Cholangitis (PBC)
Serology marker of PBC is AMA. This marker can be 
detected in > 95% PBC patients and even can be detected 
before the presence of clinical symptoms and liver 
function abnormalities. AMA can be detected through 
indirect immunofluorescence (IIF), immunoblotting 
and enzyme linked immunosorbent assay (ELISA).10 
Antimitochondrial antibody recognizes oxoacid 
dehydrogenase complex subunits (2-OADC) inside 
the mitochondria which comprises of pyruvate 
dehydrogenase complex (PDC), 2-oxoglutarate 
dehydrogenase complex (OGDC), branch chain 
2-oxoacid dehydrogenase complex (BCOADC).5,10 In 
PBC patients, 30-50% of other specific autoantibodies 
which is antinuclear antibody (ANA) can be detected.1,5 
More than 99% ANA is detected in PBC patients with 
negative AMA, thus ANA can be used as diagnostic 
tool in PBC patient with negative AMA.2 ANA 
 
 9
Figure 3. ANA appearance in PBC. A. Multiple nuclear dots pattern. B. Nuclear rim pattern11 
Pathogenesis
The aetiopathogenesis of PBC is the interaction between genetic and environmental 
factors which eventually causes immune reaction towards biliary epithelial cells, involving 
the natural and acquired immune response towards an autoantigen.1,5
Genetic factors 
There are several evidences that genetic factors have a strong role in the 
etiopathogenesis of PBC. Six percent of PBC patient has a first line family hereditary of 
PBC or other autoimmune disease.1,2,4,12 PBC is more dominant to happen in female, which 
is predicted to be caused by the changes in X chromosome.13
According to genome-wide association studies (GWAS), Human Leukocyte 
Antigen (HLA) gene class II such as HLA-DRB1, HLA-DQA1 and HLA-DQB1 has a 
strong relation to individual susceptibility to PBC.5,13,14 Possessing non-HLA gene may 
also contribute to the pathogenesis of PBC in 80-90% of PBC patient with no HLA gene 
associated with susceptibility to PBC. These genes include IRF5, SOCS1, TNFAIP3, 
which function as antigen presentation; TNFSF15, IL12R, TYK2, STAT4, which function 




Figure 3. ANA appearance in PBC. A. Multiple nuclear dots 
pattern. B. Nuclear rim pattern11
exami ation with IIF m thod give a ucl ar rim and 
multiple nuclear dots pattern appearance (figure 3).1,5,7 
Pathogenesis
The aetiopathogenesis of PBC is the interaction 
between genetic and environmental factors which 
eventually causes immune reaction towards biliary 
epithelial cells, involving the natural and acquired 
immune response towards an autoantigen.1,5
Genetic Factors
There are several evidences that ge etic factors 
have a strong role in the etiopathogenesis of PBC. Six 
percent of PBC patient has a first line family hereditary 
of PBC or other autoimmune disease.1,2,4,12 PBC is more 
dominant to happen in female, which is predicted to be 
caused by the changes in X chromosome.13 
According to genome-wide association studies 
(GWAS), human leukocyte antigen (HLA) gene class II 
such as HLA-DRB1, HLA-DQA1 and HLA-DQB1 has 
a strong relation to individual susceptibility to PBC.5,13,14 
Possessing non-HLA gene may also contribute to the 
pathogenesis of PBC in 80-90% of PBC patient with 
no HLA gene associated with susceptibility to PBC. 
These genes include IRF5, SOCS1, TNFAIP3, which 
function as antigen presentation; TNFSF15, IL12R, 
TYK2, STAT4, which function to activate T cell and 
IFN production; and ARID3A which function on B cell 
activation and immunoglobulin production.14 
Environmental Factors
Bacterial infection and xenobiotic are environmental 
factors that can cause the diminished ability of 
tolerance toward autoantigen, hence produce AMA. 
2,3 In several studies, consistently stated that there is 
an association between PBC and bacterial infection, 
which can be caused by Escherichia coli, Chlamydia 
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pneumoniae, Lactobacillus delbrueckii, Helicobacter 
pylori, Novosphingobium aromaticivorans. Human 
PDC-E2 molecule mimics the PDC-E2 of the before 
mentioned microorganisms, located in ExDK sequence 
which is important in the recognition of CD4+ T cells. 
Therefore, infection of those microorganisms can trigger 
the destruction of immune tolerance towards PDC-E2 
through molecular mimicry and cross reaction.2,3,4,5,15 
Xenobiotic is also involved in the etiopathogenesis 
of PBC.10 Several pharmaceutical and household 
compounds like detergent can potentially be harm, 
especially those which have molecular similarity to 
PDC-E2. 2-octynamide compound, a derivation form of 
2-Octynoic acid, can modify PDC-E2 in lipoyl domain. 
This compound is widely used for perfumes, beauty 
products particularly lipstick and nail polish, and also 
in artificial flavour for food and bubble gum.2,4,5,12,15,16 
Biliary epithelial cells
The target of PBC destruction is very specific, i.e. 
the destruction in biliary epithelial cells. Several factors 
such as molecular expression, mucosal immunity, and 
contribution in bile acid transportation and apoptosis 
characteristics, senescence, and autophagy in biliary 
epithelial cell are known to be involved in the 
development process of PBC.5 
Molecular expression
Biliary epithelial cell may play role as APC, expressing 
adhesion and accessories molecules. Adhesion molecules 
function to adhere and recognise lymphocyte, which 
include ICAM-1, VCAM-1, LFA-1 and E-selectin.3 
Biliary epithelial cell expresses accessory molecules as 
co-stimulator signal to T cell which are CD 80, CD 86 
(B7-1, B7-2). Additionally, biliary epithelial cell also 
express MHC class I and II, TNFα, IFN-γ and IL-1, 
IL-4, IL-6, and MCP-1, which secretion occur due to 
stimulation from proinflammation cytokines.4,5
Mucosal immunity
The role of mucosal immunity in PBC is shown by 
the biliary epithelial cells which transfer IgA actively 
through epithelial mucosa. Immunoglobulin A (subtype 
AMA) recognizes PDC-E2 which can be found in 
serum, saliva, urine and bile. This has been proven by 
the detection of IgA and PDC-E2 deposit in the apical 
surface and cytoplasm of biliary epithelial cells.2,5
Bile Acid Transportation
Biliary epithelial cell has anion exchanger 2/AE2 
(SLC4A2) regulation which plays role in the defence 
of “bicarbonate umbrella bilier”, functioning as bile 
protection. In PBC, SCL4A2 regulation is destructed 
causing the excessive accumulation of bile acid 
(cholestasis). This causes progressive biliary lesion 
up to ductopenia due to the toxic characteristics of 
bile. Bile acid accumulation is a ligand to Farnesoid 
x receptor (FXR) that functions in the regulation of 
bile acid homeostasis, lipid, glucose metabolism and 
for immune regulation. FXR activation inhibit the 
signalling cascade of nuclear factor κB (NF-κB) by 
decreasing the production of TNF-α, IL-1, IL-17 and 
IFN-γ.4,5,17
Apoptosis
Biliary epithelial cell (BEC) is prone to apoptosis. 
Several stimuli originating from immune system, 
oxidative stress, toxin, and infectious agent can 
induce apoptosis of BEC.18 Biliary epithelial cell 
will phagocytize apoptotic biliary epithelial cell and 
form apotop which later becomes the endogen source 
of new autoantigen formation. Circulating AMA 
will recognise apoptop and forms AMA autoantigen 
complex. This complex will cause apoptosis around 
the cell.2,5,12 
Senescence
In PBC, it was found that accumulation of biliary 
epithelial that has undergone senescence is marked 
by the increased expression of senescence marker, 
like the senescence-associated beta-galactosidase 
(SA-βgal), p16INK4A, and p21Waf1/Cip1. The mechanism 
is still unclear. After senescence, injured cells will 
normally be substituted with new cells, but in PBC 
cell undergoes transition to senescence-associated 
secretory phenotype (SASP), that is marked by the 
secretion of chemokines (CX3CL1, CXCL8 and 
CCL2), cytokine (IL-6, IL-1), growth factors and 
metalloproteinase matrix (MMPs) which function is 
to repair/remodel and attracting immune cells.12
Autophagy 
Autophagy is a cell defence mechanism when cell 
suffers from lesion or nutritional deprivation. It works 
by destructing and recycling intracellular organelles. 
Autophagy regulation is maintained by immunity 
signal molecules, which are toll like receptors (TLR), 
IFN-γ and NF-κ. Autophagy process can be a signal 
for apoptosis.18
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In PBC, autophagy and deregulation of autophagy 
is disrupted. Immunohistochemistry examination can 
be used to detect autophagy using markers like LC3 
(accumulation of abnormal autophagosome) and p62 
(insufficient autophagy capacity).18
Mechanism of development of biliary epithelial cell 
injury in PBC 
Bacterial component with the structure mimicking 
epitope PDC-E2, xenobiotic compounds which modify 
PDC-E2 and biliary epithelial cells which undergo 
apoptosis will produce autoantigen, causing destruction 
of biliary epithelial cells in PBC. This antigen will 
activate macrophage to present antigen to CD4+ T cell 
through class II MHC and produce cytokines IL-23, 
IL-12, IFNg, TNFα. CD4+ T cells then activate and 
produce cytokines IFNg and TNFα. IFNg cytokine 
function to activate cytotoxic T cell, TNFα function to 
induce apoptosis and senescence of biliary epithelial 
cells, IL 12 function to activate Th1 cell and IL-23 which 
function to activate Th17 cell. CD4+ T cell to activate 
B cell through costimulary molecule CD40/CD40L 
and produce IL-4 to differentiate B cell into plasma 
cell which later develop antibody, particularly AMA.12
Primary Biliary Cholangitis (PBC) Treatment
United States Food and Drug Administration 
recommend Ursodeoxycholic acid (UDCA) as the 
first line treatment of PBC. Ursodeoxycholic acid 
plays role in decreasing periportal inflammation 
process and repair ductular proliferation to slow down 
development of fibrosis and, in some cases, to reduce 
the risk of oesophageal varices in PBC. Administration 
of UDCA in early stage can inhibit disease progression 
and mortality risk thus decrease the need of liver 
transplantation. UDCA treatment give response after 
6 months up to 2 years after therapy is initiated. 
Combination of UDCA and budenoside is used in 
the case of PBC and AIH overlapping syndrome. 
This combination is contraindicated for PBC patient 
with cirrhosis due to the increased of portal vein 
thrombosis.2,4,19
Obeticholic acid (OCA) and fibrate is used as the 
second line treatment for PBC. Obeticholic acid is a 
farnesoid x receptor (FXR) agonist which play role 
to regulate bile acid haemostasis, antiinflammation, 
and antifibrosis. Fibrate give anti-inflammatory effect 
and modulate bile acid synthesis through activation of 
peroxisome proliferator-activated receptor α (PPAR-α) 
pathway.2,4,20
Liver transplantation is a definitive therapy for 
PBC that develops into advanced stage even though 
pharmacological treatment has been administered. The 
survival rate of PBC after transplantation is 80% for 
2 years and 70% for 7 years. New regiment for PBC 
has been identified, serves as an immunomodulator 
targeting immune response. Rituximab and Abatacept 
is the example of this line which is still evaluated for 
its effectiveness.2,4
Differential Diagnosis of Primary Biliary Cholangitis 
(PBC)
Mechanical Obstruction of Biliary Duct 
Biliary duct obstruction due to stones, biliary 
stricture and benign or malignant tumour can give 
appearances similar to PBC. Using USG, CT scan, 
and AMA examination, we can differentiate them 
from PBC. Histopathology appearances of mechanical 
obstruction are edema of the portal tract and varied 
duct reaction with lymphoplasmatic inflammation, 
which are not distinct from PBC. Cholestasis usually 
happen in the mechanical obstruction of biliary duct, 
while cholestasis in PBC is not seen in early stage.4
Primary Sclerosing Cholangitis (PSC)
Histological appearance of PSC alone cannot be 
used as a fundamental finding to differentiate PSC 
from PBC since there is a lot of overlap morphology. 
Information regarding history of inflammatory bowel 
disease (IBD), AMA negative and a positive biliary 
tree cholangiography (gold standard) can confirm the 
diagnosis of PSC.4
Adverse Drug Reaction
Appearance of liver biopsy due to adverse drug 
reaction may be similar to PBC. Adverse drug reaction 
can be confirmed if the results of AMA examination 
are negative and there is history of drugs use, 
such as hormonal steroid (estrogen and androgen), 
phenothiazine, anticonvulsant, tricyclic anti depressants 
or antibiotics such as erythromycin, clavulanate 
amoxicillin.9
Autoimmune Hepatitis (AIH)
In AIH, there is an increase of ALT ≥5x normal 
range, increased IgG 2x normal range, slightly 
increased or normal ALP, positive ANA and SMA, 
with negative AMA. There is 20% cases of AIH show 
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positive AMA. Histopathological appearance in the 
form of hepatocellular injury without the involvement 
of bile duct and lymphocytic interface help to 
differentiate AIH from PBC. Therefore, combination 
from clinical appearance, liver function and serology 
examination results, and histopathological appearance 
are needed to confirm the diagnosis.9
Viral hepatitis
Chronic hepatitis C can have histopathological 
appearance of biliary duct lesion and granuloma in 
portal tract (particularly with interferon therapy) which 
can also be seen in PBC. Information about negative 
AMA, positive viral serological examination, ALT/
AST increase, normal or slight increase of ALP and 
absence of copper periportal deposit can help the 
diagnosis of viral hepatitis.4
CONCLUSION
Primary biliary cholangitis is an autoimmune liver 
disease which is chronic and progressive, marked 
by the presence of cholangitis and small bile duct 
destruction, which eventually may cause cirrhosis or 
even liver failure. Diagnosis of PBC is established if 
AMA titre is ≥1:40 or AMA level > 0.1unit, increased 
ALP >1,5x normal range for 6 consecutive months, 
and increased GGT. Based on the necroinflammation 
activity and histopathology variation, PBC is classified 
into mild, moderate, and severe stage. Liver biopsy is 
needed in PBC suspected patients with negative AMA 
and in PBC-AIH overlap syndrome and to evaluate 
the progressivity of the disease and response to 
therapy. The etiopathogenesis of PBC is an interaction 
between genetic factors (HLA and non-HLA genes) 
with environmental factors (bacterial infection and 
xenobiotic) which cause PDC-E2 as an autoantigen 
and the formation of AMA. 
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